At 16.3% CAGR, the North America Asparaginase Market is projected to be worth US$ 660.94 million by 2028, says Business Market Insights          

According to Business Market Insights’ research, the North America asparaginase market was valued at US$ 267.71 million in 2022 and is expected to reach US$ 660.94 million by 2028, registering an annual growth rate of 16.3% from 2022 to 2028. Rising incidences of leukemia and increasing usage application and significant growth of pharmaceutical and food industry are the critical factors attributed to the market expansion.                     

Asparaginase is an enzyme, derived mostly from bacteria, and has wide application in the food and pharmaceutical industry. Asparaginase is widely used to treat various conditions, such as acute myeloid leukemia, acute lymphoblastic leukemia, non-Hodgkin's lymphoma, and other diseases. Over the period, the prevalence of such diseases has increased significantly, creating a demand for effective treatment options. L-asparaginase is an important chemotherapeutic agent used to treat lymphoma and leukemia. L-asparaginase breakdown asparagine from blood serum, leading to the death of tumor cells due to the lack of an essential factor for protein synthesis. However, healthy cells are not affected as they can produce asparagine using L-asparagine synthetase, which is present in adequate quantity. Moreover, it is also found to be effective in preventing metastasis from solid tumors.  Asparaginase is a naturally occurring substance that is present in mammals, birds, yeast, plants, and different types of bacteria but Enterobacteriaceae family microorganisms are one of the primary sources of L-asparaginase production. Additionally, there is various research going on for the expansion of its application area in different industries, such as nanomedicine, biomedical engineering, and many more, which is contributing to the market growth. Furthermore, increasing allergic reactions from E. coli, derived L-asparaginase has increased the use of E. chrysanthemi derived L-Asparaginase. There are new production methods for asparaginase are developing, which include new bacterial strains, such as Pseudomonas fluorescens, Escherichia coli, Serratia marcescens, Erwinia carotovora, Saccharomyces cerevisiae, and Proteus vulgaris. A few genres of fungi are also used, such as Penicillium, Aspergillus, and Fusarium. These factors are boosting the asparaginase market significantly.

On the contrary, side effects associated with use of asparaginase hurdles the growth of North America asparaginase market. 

• Based on type, the North America asparaginase market is segmented into escherichia coli, erwinia chrysanthemi, pegylated, and others. The escherichia coli segment held 49.0% market share in 2022, amassing US$ 131.20 million. It is projected to garner US$ 332.20 million by 2028 to expand at 16.7% CAGR during 2022–2028.  
• Based on application, the North America asparaginase market is segmented into therapeutic, food processing, and others. The therapeutic segment held 60.6% market share in 2022, amassing US$ 162.24 million. It is projected to garner US$ 408.57 million by 2028 to expand at 16.6% CAGR during 2022–2028. The therapeutic segment is further classified into acute lymphoblastic leukemia, lymphoblastic lymphoma, and others.
• Based on end-use industry, the North America asparaginase market is bifurcated into healthcare and food manufacturing. The healthcare segment held 59.4% market share in 2022, amassing US$ 159.07 million. It is projected to garner US$ 395.76 million by 2028 to expand at 16.4% CAGR during 2022–2028.     
• Based on country, the North America asparaginase market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 85.0% market share in 2022. It was assessed at US$ 227.47 million in 2022 and is likely to hit US$ 569.31 million by 2028, exhibiting a CAGR of 16.5% during the forecast period.      

Key players dominating the North America asparaginase market are Biovendor, LLC; Changzhou Qianhong Biopharma Co Ltd; Creative Enzymes; Jazz Pharmaceuticals, Inc.; medac GMBH; Servier Pharmaceuticals LLC; Taj Pharmaceuticals Limited; and United Biotech (P) Limited among others.   

• In May 2021, Jazz Pharmaceuticals acquired GW pharmaceutical company to enhance the R&D capabilities.

• In April 2021, Servier completed acquisition of Agios Pharmaceuticals’ $2 billion plus royalties which include commercial, clinical, and research-stage oncology portfolio. This acquisition strengthens Servier’s commercial presence in the U.S. malignant hematology market and provides the potential for long-term growth into the solid tumor space.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com